Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy

Core Insights - Akeso has completed patient enrollment in a Phase III study for ivonescimab, targeting advanced biliary tract cancer, comparing it with durvalumab combination therapy [1] - Ivonescimab has shown significant positive results in previous Phase III studies, leading to its approval for PD-L1-positive non-small cell lung cancer [2][3] - The drug targets both PD-1 and VEGF, providing a synergistic anti-tumor effect, establishing it as a leader in immunotherapy [4] Company Overview - Akeso is a biopharmaceutical company focused on innovative biological medicines, with a robust pipeline of over 50 assets in various disease areas [10] - The company utilizes a unique integrated R&D innovation system and has developed a GMP-compliant manufacturing system [10] - Akeso aims to provide affordable therapeutic antibodies globally while creating commercial and social value [10] Development Strategy - Akeso is implementing a dual-path strategy to maximize ivonescimab's value, focusing on domestic commercialization in China and global development partnerships [5] - The company has an extensive clinical foundation with over 20 Phase II studies across more than 10 tumor types, facilitating rapid transition to registrational studies [3]